KU Leuven
Leuven, 3000, Belgium
Location status: Recruiting
NCT Number: NCT05651386
The six food elimination diet, as known in eosinophilic esophagitis, will be performed in 15 patients with functional dyspepsia (subtype postprandial distress syndrome). Screening will exclude patients with allergies by performing immunocaps on blood. Before and after the 8 weeks of diet, an gastroduodenoscopy with biopsies will be performed to evaluate duodenal eosinophilia, mast cells and permeability. To evaluate gastric sensorimotor function, a gastric emptying breath test and a barostat test will be performed before and after the diet.
Symptoms will be monitored with a daily diary (LPDS diary) and food intake will be evaluated during 2 weeks.
If there is an improvement of symptoms during the diet, a reintroduction period will start. This period will last 6 weeks. Every 2 weeks, two food groups will be reintroduced. When there is a clear worsening in symptoms, a new endoscopy with biopsies will be performed.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Not applicable
Leuven, 3000, Belgium
Location status: Recruiting
To assess the effect of the six food elimination diet on duodenal eosinophilia, an interventional study will be conducted in 15 patients.
The study design includes 8 weeks of a strict 6 food elimination diet, followed by an 8 week reintroduction phase in patients with symptom improvement. The duration of 8 weeks is based on the effect of the 6 FED in eosinophilic esophagitis.
Each subject will undergo a screening before the start of the diet. During the screening visit, all study procedures will be explained, the informed consent form will be signed by the participant, and the inclusion and exclusion criteria will be checked by revising the participant's medical history and by using screening GI symptom questionnaires (Rome IV questionnaire).
The screening visit will include a physical examination, medical history and a blood sample for IgE testing to exclude typical food allergies.
When eligibility is confirmed during the screening visit, a fourteen-day period starts. In this period, the LPDS diary (Leuven Postprandial distress syndrome) and food diary will be filled out on a daily basis to assess symptoms at baseline. The food diary will be available via an application for mobile phones or online use. The Comprehensive Nutrition Assessment Questionnaire will be filled in to analyse baseline food intake.
At visit 1, following tests will be conducted in a 2-day period (outpatient clinic):
The diet will be followed during 8 weeks under supervision of this dietician with experience in eosinophilic esophagitis.
During the 6FED the compliance of patients will be evaluated by the use of diet diaries from week 6 to 8. Symptoms will be evaluated throughout the 8-week dietary restriction period using the daily LPDS diary. Patients will report daily food intake via an application for mobile phone or online use during two weeks of the diet period.
A telephone call will be scheduled after two and six weeks, to assess compliance.
After 8 weeks of six food elimination diet, a new gastroduodenoscopy with biopsies will be performed, as well as a new gastric barostat and gastric emptying breath test, as described at visit 1.
At visit 2, patients with a symptom improvement, defined as an average LPDS with 0.5 point or more compared to baseline will be sent for a consultation with our dietician for the explanation of reintroduction of nuts and fish.
This will be done in a non-blinded way.
During the reintroduction period, patients will visit the hospital every 2 weeks for visit 3, 4 and 5. First, fish and nuts will be reintroduced, than eggs and soy and lastly gluten and milk. Patients with symptom worsening, defined as an average LPDS with 0.5 point or more compared to the end of the 6FED diet period, will be invited to undergo a with gastroscopy with biopsies and a new blood sample for PBMCs.
During the entire study, patients will fill in the daily diary (LPDS).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No blinded, no controlled intervention.
Time frame: 8 weeks
Measured with duodenal biopsies with H&E staining
Time frame: 8 weeks
Measured with duodenal biopsies with immunohistochemistry
Time frame: 8 weeks
Measured with duodenal biopsies with ussing chambers
Time frame: 8 weeks
Measured with daily symptom diary (LPDS)
Time frame: 8 weeks
Measured with PAGI-SYM
Time frame: 8 weeks
Measured with OSS
Time frame: 8 weeks
Measured with OTE
Time frame: 8 weeks
Measured with SF-NDI
Contact information is provided by the study sponsor or research team.
Universitaire Ziekenhuizen KU Leuven
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06360900
Functional Dyspepsia
Boston, Massachusetts, United States
View Trial DetailsNCT07694778
Functional Dyspepsia
Dhaka, Bangladesh
View Trial DetailsNCT06854120
Digestive System Diseases, Functional Dyspepsia
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT07584473
Celiac Disease, Colonic Diseases
Palermo, PA, Italy
View Trial Details